The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro

Although several clinical trials are now underway to test possible therapies, the worldwide response to the COVID-19 outbreak has been largely limited to monitoring/containment. We report here that Ivermectin, an FDA-approved anti-parasitic previously shown to have broad-spectrum anti-viral activity...

Descripción completa

Detalles Bibliográficos
Autores principales: Caly, Leon, Druce, Julian D., Catton, Mike G., Jans, David A., Wagstaff, Kylie M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier B.V. 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7129059/
https://www.ncbi.nlm.nih.gov/pubmed/32251768
http://dx.doi.org/10.1016/j.antiviral.2020.104787
_version_ 1783516702540038144
author Caly, Leon
Druce, Julian D.
Catton, Mike G.
Jans, David A.
Wagstaff, Kylie M.
author_facet Caly, Leon
Druce, Julian D.
Catton, Mike G.
Jans, David A.
Wagstaff, Kylie M.
author_sort Caly, Leon
collection PubMed
description Although several clinical trials are now underway to test possible therapies, the worldwide response to the COVID-19 outbreak has been largely limited to monitoring/containment. We report here that Ivermectin, an FDA-approved anti-parasitic previously shown to have broad-spectrum anti-viral activity in vitro, is an inhibitor of the causative virus (SARS-CoV-2), with a single addition to Vero-hSLAM cells 2 h post infection with SARS-CoV-2 able to effect ~5000-fold reduction in viral RNA at 48 h. Ivermectin therefore warrants further investigation for possible benefits in humans.
format Online
Article
Text
id pubmed-7129059
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher The Author(s). Published by Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-71290592020-04-08 The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro Caly, Leon Druce, Julian D. Catton, Mike G. Jans, David A. Wagstaff, Kylie M. Antiviral Res Article Although several clinical trials are now underway to test possible therapies, the worldwide response to the COVID-19 outbreak has been largely limited to monitoring/containment. We report here that Ivermectin, an FDA-approved anti-parasitic previously shown to have broad-spectrum anti-viral activity in vitro, is an inhibitor of the causative virus (SARS-CoV-2), with a single addition to Vero-hSLAM cells 2 h post infection with SARS-CoV-2 able to effect ~5000-fold reduction in viral RNA at 48 h. Ivermectin therefore warrants further investigation for possible benefits in humans. The Author(s). Published by Elsevier B.V. 2020-06 2020-04-03 /pmc/articles/PMC7129059/ /pubmed/32251768 http://dx.doi.org/10.1016/j.antiviral.2020.104787 Text en © 2020 The Author(s) Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Caly, Leon
Druce, Julian D.
Catton, Mike G.
Jans, David A.
Wagstaff, Kylie M.
The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro
title The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro
title_full The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro
title_fullStr The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro
title_full_unstemmed The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro
title_short The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro
title_sort fda-approved drug ivermectin inhibits the replication of sars-cov-2 in vitro
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7129059/
https://www.ncbi.nlm.nih.gov/pubmed/32251768
http://dx.doi.org/10.1016/j.antiviral.2020.104787
work_keys_str_mv AT calyleon thefdaapproveddrugivermectininhibitsthereplicationofsarscov2invitro
AT drucejuliand thefdaapproveddrugivermectininhibitsthereplicationofsarscov2invitro
AT cattonmikeg thefdaapproveddrugivermectininhibitsthereplicationofsarscov2invitro
AT jansdavida thefdaapproveddrugivermectininhibitsthereplicationofsarscov2invitro
AT wagstaffkyliem thefdaapproveddrugivermectininhibitsthereplicationofsarscov2invitro
AT calyleon fdaapproveddrugivermectininhibitsthereplicationofsarscov2invitro
AT drucejuliand fdaapproveddrugivermectininhibitsthereplicationofsarscov2invitro
AT cattonmikeg fdaapproveddrugivermectininhibitsthereplicationofsarscov2invitro
AT jansdavida fdaapproveddrugivermectininhibitsthereplicationofsarscov2invitro
AT wagstaffkyliem fdaapproveddrugivermectininhibitsthereplicationofsarscov2invitro

Ejemplares similares